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Abstract
Mucus-penetrating Nanosuspensions, consisting of pure hydrophobic therapeutics with dense 
muco-inert coatings that enable particles to effectively bypass the mucus barrier, demonstrate 
superior drug distribution and absorption at mucosal surfaces. With significantly increased drug 
load compared to polymeric systems and established clinical translation of nanosuspensions-based 
products, mucus-penetrating nanosuspensions are a promising vehicle for improving mucosal 
delivery of poorly soluble drugs.
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Delivery systems that can more effectively deliver drugs to mucosal surfaces are needed.[1] 
For efficient delivery to mucosal surfaces, drugs and drug carriers have to first bypass the 
adhesive mucus gel, a barrier that has evolved to protect the underlying tissues by efficiently 
trapping and removing foreign pathogens or particles.[2] Mucus is a mesh that traps 
particulates both sterically and adhesively, thus size and surface characteristics play a 
significant role.[3] It was reported that nanoparticles with sizes smaller than the mucus mesh 
and densely coated with a muco-inert material (poly(ethylene glycol), or PEG), can rapidly 
diffuse through human mucus secretions.[4] These “mucus-penetrating particles (MPP)”, 
have demonstrated improved mucosal distribution, enhanced pharmacokinetics, and superior 
treatment efficacy in applications such as prevention of genital herpes infection,[5] treatment 
of cervical cancer,[6] and lung gene therapy.[7] Nanosuspensions (NS), which are nano-sized 
particulates fabricated from insoluble drug precipitates and stabilized with surface coatings, 
have become a widely used dosage form in pharmaceutical applications.[8] While prior MPP 
Yu et al. Page 2













systems have largely been based on biodegradable polymers and, thus, usually contain 20% 
drug or less by weight, NS formulated based on pure, water insoluble drugs can achieve 
higher drug content, a feature that is critical for delivery to mucosal regions with highly 
limited dosing volume/mass, such as the nasal and sinus cavities and the eyes.[9] 
Furthermore, the increased surface-to-volume ratio in NS facilitates the dissolution of the 
drugs, especially those otherwise hardly soluble under physiological conditions.[8;10] NS 
may thus be suitable for applications that require fast drug uptake,[11] such as treatment of 
acute indications, like asthma, or coitally-associated pre-exposure prophylaxis of viral 
infections, such as HIV. Additionally, the simple composition and well-established 
manufacturing practices for producing NS have accelerated clinical development, with at 
least 9 NS-based therapeutic products successfully marketed to date.[12] These favorable 
features have attracted broad interest in the development of NS formulations, especially for 
intravenous and oral administration.[12–13] However, the interactions between NS and 
mucus, as well the development of NS that can penetrate mucus barriers to improve mucosal 
drug delivery, have yet to be investigated. Here, we report the development of mucus-
penetrating NS for efficient delivery of poorly soluble drugs to mucosal surfaces.
We have previously shown that hydrophobic polymeric nanoparticles (~200–300 nm in 
diameter) with mucoadhesive surface chemistry can be made mucoinert by densely coating 
the nanoparticle surface with particular Pluronics®.[4b] Pluronics are triblock copolymers 
composed of a hydrophobic poly(propylene oxide) (PPO) core and two hydrophilic PEG 
arms. The PPO core of certain Pluronics can adsorb onto hydrophobic nanoparticle surfaces, 
while the PEG chains, at sufficient density, shield the particle surface from electrostatic and 
hydrophobic interactions with mucus.[14] We therefore first tested whether coating with 
Pluronic F127 (abbreviated as F127 hereafter) could reduce the adhesion of similarly sized 
and hydrophobic NS to mucus. F127 is a Generally Regarded As Safe (GRAS) by the FDA 
material in multiple pharmaceutical products.[4b;14] We selected curcumin (CUR) as a model 
drug to formulate NS. CUR has been widely reported as an anti-inflammatory, anti-oxidant, 
anti-tumor and anti-viral therapeutic.[15] However, the extremely low solubility of CUR in 
water leads to its poor bioavailability in vivo, and thus limits its use; CUR delivered 
systemically can also be readily metabolized and deactivated in the liver.[16] Local delivery 
of CUR as a NS formulation may therefore be an ideal approach to address these limitations. 
In addition, CUR possesses strong and stable fluorescence,[17] which allows the observation 
of CUR NS in mucus using fluorescence microscopy without the need for complicated 
labeling and alteration of CUR properties. Due to these properties, various nano-
formulations of CUR have been widely investigated, including several that employed 
Pluronics as stabilizers.[18]
We formulated CUR-F127 NS via high power probe sonication similar to conventional top-
down NS formulation approaches.[19] Powder X-ray diffractometry (XRD) confirmed that 
CUR-F127 NS preserved the crystallinity of unprocessed CUR, as the characteristic peaks of 
CUR-F127 NS matched those of the raw CUR (Figure 1a). The signature peaks of F127 
were not apparent in the XRD profile of CUR-F127 NS, suggesting that the NS were 
composed mainly of CUR and a small proportion of F127 (Figure 1a). We also measured the 
fluorescence spectrum of CUR-F127 NS to confirm that the processing did not quench the 
CUR fluorescence (Figure S1). To further show that the fluorescent signal was indeed 
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emitted from the NS, we imaged the CUR-F127 NS with both fluorescence and bright field 
microscopy. When merged, the fluorescence signal was co-localized with the particles in the 
bright field image (Figure S2). Transmission electron microscopy (TEM) showed that the 
morphology of CUR-F127 NS was relatively irregular, likely due to the randomness of the 
shearing process during probe sonication (Figure 1b). The mean diameter of CUR-F127 NS 
was 133 nm (Table 1), consistent with the average size indicated by TEM. The average mesh 
size of human mucus secretions, including cervicovaginal, airway and sinus mucus, ranges 
from ~140 to 340 nm, with a wide distribution of mesh sizes.[2a;20] Thus, the small size of 
CUR-F127 NS was appropriate for diffusion through mucus. The ζ-potential of 210 nm 
carboxylate-functionalized polystyrene nanoparticles (PS-COOH, previously reported to be 
strongly mucoadhesive [20–21]) was highly negative (Table 1), and in previous work, a 
change to near-neutral ζ-potential was indicative of effective PEG surface coating.[4] 
However, the ζ-potential of CUR-F127 NS was not necessarily indicative of the extent of 
surface coverage, as the NS were near-neutrally charged regardless of surface coating due to 
the intrinsic drug properties (Table 1). For this reason, investigation of the NS diffusion in 
mucus was essential for evaluating the effectiveness of surface coatings at reducing 
interactions with mucus.
To determine whether formulating the NS with F127 effectively coated the surface of the 
CUR, we next investigated the transport behavior of CUR-F127 NS in cervicovaginal mucus 
(CVM) freshly collected from healthy donors. We first viewed the CVM alone (i.e. without 
the addition of CUR NS) at the same settings to ensure that auto-fluorescence in the sample 
would not interfere with visualization of the CUR NS (Figure S3a). In contrast, the CUR-
F127 NS fluorescence was clearly visible as dispersed particulates in CVM (Figure S3b). 
CUR-F127 NS exhibited highly diffusive time-lapse trajectories over the course of 20 s 
movies, suggesting Brownian-like diffusion (Movie S1); in contrast, the mucoadhesive PS-
COOH nanoparticles were immobilized, exhibiting highly restricted, non-Brownian traces 
(Figure 2a). To further quantify the differences in transport rates of CUR-F127 NS and PS-
COOH particles in CVM, we measured the ensemble-averaged mean-squared displacement 
(<MSD>) of the particles as a function of time scale; greater <MSD> represents faster 
particle movement. The <MSD> of CUR-F127 NS was 4,400-fold higher than that of PS-
COOH at a time scale of 1 s (Table 1), and at least two orders of magnitude higher across all 
time scales analyzed up to 3 s (Figure 2b). The <MSD> of PS-COOH nanoparticles was 
25,000-fold lower than the theoretical MSD of similarly sized nanoparticles in water at a 
time scale of 1 s, whereas the <MSD> of CUR-F127 NS was only 9-fold lower (Table 1). 
Distributions of the logarithmic MSD (at a time scale of 1 s) of individual particles further 
demonstrate that the CUR-F127 NS were uniformly diffusive in CVM (Figure 2c). Overall, 
CUR-F127 NS demonstrated diffusion rates comparable to that of previous polymer-based 
MPP formulations.[4b–e]
We then characterized the diffusion rates of CUR-F127 NS in airway sputum freshly 
expectorated by cystic fibrosis (CF) patients (cystic fibrosis sputum; CFS), a critical barrier 
for inhaled CF therapies. In CF patients, impaired ion transport leads to a more viscoelastic 
mucus that impairs mucociliary clearance and provides a permissive environment for 
chronic infection and inflammation, further contributing to the dense mucus mesh 
structure.[3] Similar to the results in CVM, CUR-F127 NS demonstrated more diffusive 
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trajectories and increased individual MSD as compared to the mucoadhesive PS-COOH 
particles (Figure 2d–f). At a time scale of 1 s, the mobility of CUR-F127 NS was 37-fold 
slower than the theoretical speed of similarly sized nanoparticles in water (Table 1), 
comparable to that of previously reported MPP formulations in CFS. The mobility of CUR-
F127 NS in CFS was slightly more constrained than that in CVM, likely due to the smaller 
mesh size of CFS (average ~ 140 nm, with a range of 60–300 nm [20b]) and respiratory 
mucus.[20c;20d] While mucus from different anatomical regions may have different structural 
properties, this and other work suggests that an effective mucoinert surface coating will 
generally reduce adhesion to various types of mucus secretions.[2a;4e;22] These results 
suggest that CUR-F127 NS may penetrate mucus at multiple mucosal surfaces, even in 
diseased states, and therefore may be broadly useful for various applications. In addition, 
CUR-F127 NS showed dissolution rates over 30-fold faster than that of raw CUR (Figure 
S4); this enhanced dissolution capability should facilitate the rapid absorption of CUR by 
target tissues.[23]
To further understand the formulation requirements for muco-inert NS coatings, we 
examined the mobility in human CVM of CUR NS formulated at different F127 
concentrations. While all formulations exhibited sizes below the average mesh spacing of 
CVM, the size of CUR NS increased as the concentration of F127 decreased, suggesting that 
F127 exerts a stabilizing effect on the CUR NS during fabrication (Table 1). CUR NS 
prepared with minimal (0.001%) F127 solution showed significantly reduced mobility in 
CVM similar to that of PS-COOH particles, reflecting the mucoadhesive nature of the 
hydrophobic CUR NS core and lack of muco-inert coating. A 10-fold increase of F127 
concentration to 0.01% resulted in an over 300-fold increase of the <MSD> of CUR NS in 
CVM, and further increases in F127 concentrations resulted in incremental increases in the 
<MSD>. The over 300-fold increase in <MSD> between 0.001% and 0.01% F127 suggested 
an increase in the adsorption of F127 onto the surface of CUR, providing effective coatings 
even within this low concentration range. Effective adsorption of F127 is likely critical for 
maintaining NS stability and the ability of the NS to resist mucoadhesion. The wide range of 
effective F127 concentrations that provide effective muco-inert coatings may also provide 
more engineering flexibility for formulation optimization specific to different fabrication 
methods or applications.[19]
We screened 11 additional Pluronics and 3 other PEG-containing surfactants (i.e., Tween® 
20, Tween® 80 and Vitamin E-TPGS) to establish selection criteria for materials that are 
suitable as muco-inert NS coatings. Many of the CUR NS formulated in the presence of 
Pluronics demonstrated improved mobility in CVM as compared to the mucoadhesive 200 
nm PS-COOH, with notable exceptions (Figure 3 and Table S1). In contrast, the 3 PEG-
containing surfactants tested failed to provide sufficient PEG coatings on CUR NS to reduce 
adhesion in CVM (Table S2). To investigate the underlying phenomenon determining 
whether the Pluronics formed a sufficient muco-inert coating on the CUR NS, we mapped 
the <MSD> of CUR-Pluronics NS as a function of the molecular weight (MW) of the 
Pluronic PPO and PEG segments. As shown in Figure 3, the mobility of CUR-Pluronics NS 
correlated with the PPO MW (correlation coefficient r = 0.94), but was independent of PEG 
MW (r=0.12), with effective shielding achieved at PPO MW above ~ 2.6 kDa regardless of 
PEG MW (~ 0.7–5.8 kDa). Similarly, the non-Pluronic surfactants containing PEG chains of 
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MW (~1 kDa) comparable to the Pluronics that effectively coated the CUR NS (e.g. P123), 
but lower MW hydrophobic segments (~0.3–0.5 kDa), failed to form a sufficient muco-inert 
coating on the CUR NS (Table S2), further suggesting that the effectiveness of the surface 
coating is dependent on the affinity of the hydrophobic segments to the NS surface. A high 
affinity interaction would lead to efficient adsorption of the surfactant onto the NS surface, 
and thus provide a highly compacted, brush-like PEG surface layer even at PEG MW as low 
as ~ 750 Da (i.e., P103).[24] These engineering principles provide general guidelines for the 
selection or design of appropriate surfactants that enable NS, and other hydrophobic carriers 
as previously suggested,[4b;25] to bypass mucus and potentially other adhesive biological 
barriers.[26] Although we have demonstrated that surface coating by certain Pluronics is 
sufficient to reduce adhesive interactions of nanosuspensions with the mucus mesh, it has yet 
to be studied whether a protein corona forms on the surfaces of Pluronic-coated 
nanoparticles in mucus.[27] It is not necessarily expected that nanosuspensions will be taken 
up by cells as intact nanoparticles, but such surface modifications could potentially affect 
cell uptake and intracellular trafficking of Pluronic-coated nanoparticles that are internalized 
intact in vivo.
We next investigated whether CUR-F127 NS diffusion in mucus would lead to improved 
mucosal surface distribution in vivo. We selected raw CUR and CUR NS coated with F68 
(CUR-F68 NS), another Pluronic that is widely used in pharmaceutical products,[4b;14] to 
compare to the muco-inert CUR-F127 NS. Based on the screening results, F68 was an 
insufficient coating material for the NS (Movie S2), as the average diffusion rates of F68-
CUR NS were ~20-fold slower than CUR-F127 NS in CVM at a time scale of 1 s (Table 1). 
Moreover, we confirmed that the CUR-F68 NS was not stable when incubated in a model 
mucin solution, further suggesting that the F68 does not provide a sufficient surface coating 
to prevent interactions with mucins (Figure S5). In contrast, the average size of the CUR-
F127 NS remained relatively constant during 12 h of incubation in mucin solution (Figure 
S5). Mice were dosed intranasally to examine CUR distribution in the mouse airways. 
Representative images of transverse sections of the large airways are shown in Figure 4a. 
These images were used to quantify the uniformity (coefficient of variation, C.V.) and 
overall coverage of CUR distribution, measured as a percentage of the epithelium with 
fluorescence above the tissue background (Figure 4b,c). Lower C.V. values and higher 
percentages of coverage represent improved mucosal drug distribution. Raw CUR were 
aggregated within the airway lumen and provided limited coverage of the mucosa (C.V. = 
2.14 ± 0.12, coverage = 11 ± 3%). Both the large size and hydrophobicity of the raw CUR 
can lead to trapping in the mucus gel.[4e] While both the F68- and F127-containing NS 
formulations provided improved surface coverage compared to raw CUR, CUR-F68 NS 
showed aggregation and incomplete coverage of the epithelium (C.V. = 0.99 ± 0.06, 
coverage = 70 ± 7%), suggesting that the insufficient surface coating by F68 compromised 
the mucosal distribution of the NS.[4a] In contrast, CUR-F127 NS provided highly uniform 
and near complete CUR distribution across the entire epithelial surface (C.V. = 0.49 ± 0.02, 
coverage = 91 ± 5%). It is notable that in airways treated with the NS formulations, a 
significant amount of drug fluorescence was found associated with the epithelial tissue, 
which is likely due to the enhanced dissolution of the NS (Figure 4a). In contrast, 
fluorescence from raw CUR was isolated to the aggregates in the airway lumen. It is 
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possible that drugs within the epithelial layer may penetrate deeper into the underlying tissue 
via transcellular or paracellular mechanisms over a prolonged duration.[1a;28] The muco-
inert coating of the NS likely further increases drug absorption by the tissue, as the coating 
prevents agglomeration in mucus, which would negatively impact the dissolution profile of 
the NS.[29]
Finally, we investigated whether the approach developed here would be applicable to NS 
composed of other hydrophobic therapeutics. We formulated F127-coated NS consisting of 
meso-tetra-(4-hydroxyphenyl) porphyrin (p-THPP), an investigative photo-sensitizer for 
photodynamic therapy.[30] Similar to CUR, p-THPP is water insoluble and possesses 
intrinsic fluorescence.[31] p-THPP-F127 NS displayed crystalline stability and shear-induced 
irregular morphology similar to those of CUR-F127 NS (Figure S6a,b). While the average 
size of p-THPP-F127 NS was larger than CUR-F127 NS (mean diameter = 323 nm, Table 
1), their mobility in human CVM was comparable to that of CUR-F127 NS, with <MSD> at 
a time scale of 1s only 5-fold slower than the theoretical diffusion rates of similarly size 
nanoparticles in water (Table 1). Furthermore, p-THPP-F127 NS demonstrated enhanced 
dissolution rates compared to raw p-THPP (Figure S6c), and uniform distribution in the 
mouse airways following inhalation (Figure S6d). These results imply that our approach for 
developing muco-inert drug NS can be applied to other water insoluble drugs that form NS 
in aqueous solutions.
In summary, we developed mucus-penetrating NS composed of model poorly water soluble 
drugs, namely CUR and p-THPP, and coated with select Pluronics, in particular F127, which 
formed a muco-inert coating on the drug particulate surfaces. We showed that the coating 
efficiency by various materials was impacted by the MW of the hydrophobic segments of the 
surfactants and, therefore, their ability to coat the hydrophobic surfaces of the NS. The 
crystalline states of the drugs were maintained in the NS formulations, but their dissolution 
rates were greatly increased. In the mouse airways, mucus-penetrating NS provided 
improved mucosal distribution and appeared to enhance drug absorption by the epithelial 
tissues. Moreover, the all GRAS composition of mucus-penetrating NS and the success of 
existing NS-based clinical products should accelerate the translational development of the 
NS platform. Mucus-penetrating NS have great potential for treatment of diseases at 
mucosal surfaces, and potentially other tissues with similarly obstructive biological barriers, 
including brain tissues and peritoneal fluids.[26]
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Physical characterization of CUR-F127 NS. a) Powder X-ray diffraction (Powder-XRD) 
diagram of F127, raw curcumin (Raw CUR) and CUR-F127 NS. b) Representative TEM 
image of CUR-F127 NS.
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Transport behavior of uncoated PS-COOH nanoparticles and CUR-F127 NS in a–c) human 
cervicovaginal mucus (CVM) (Left) and d–f) cystic fibrosis sputum (CFS) (Right). a&d) 
Representative trajectories of PS-COOH nanoparticles and CUR-F127 NS. b&e) Ensemble 
averaged geometric mean-squared displacements (<MSD>) as a function of time scale. c&f) 
Distributions of the logarithms of individual particle MSD at a time scale of 1 s. Data 
represent the ensemble average of five independent experiments, with n ≥ 100 particles 
tracked for each experiment. Error bars indicate geometric standard error. (**, p<0.01 for all 
time scales analyzed).
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Mobility of CUR NS formulated with different Pluronics coatings in human CVM. a) Phase 
diagram correlating <MSD> at a time scale of 1s of CUR NS to the MW of the Pluronics 
PEG segments and the poly(propylene oxide) (PPO) segment. Each data point represents a 
specific type of Pluronic, as indicated. b–c) <MSD> at a time scale of 1 s as a function of the 
MW of b) PEG or c) PPO segments. The insets represent the same plot with linear scale of 
<MSD>, while r represents the correlation coefficient. Data represent the ensemble average 
of at least three independent experiments, with n ≥ 100 particles tracked for each 
experiment. Error bars indicate geometric standard error.
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Distribution of CUR-F127 NS, CUR-F68 NS and Raw CUR in mouse airways. a) 
Transverse frozen sections of mouse trachea tissue following intranasal administration of NS 
or raw drug suspension. Red represents CUR fluorescence. Arrows indicate drug aggregates. 
Scale bars represent 500 μm. b) Coefficient of variations (C.V.) of fluorescence intensity 
profiles along the airway epithelial surface. Lower C.V. represents better uniformity of 
distribution. c) Percent coverage of CUR along the airway epithelial surface. (*, p < 0.05; 
**, p < 0.01; n = 5 mice for each group.)
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Table 1
Size and ζ-potential of F127 and F68-coated NS formulations and uncoated PS-COOH nanoparticles with 
ratios of their ensemble average MSD in human CVM (<MSD>m) compared to the theoretical diffusion rates 
in water (MSDw).
NS/Particle Type Mean Diameter [nm]a ζ-Potential [mV]a MSDw/<MSD>mb
in CVM in CFS
CUR-F127 133 ± 12 − 0.8 ± 0.1 9 37
CUR-0.1%F127 154 ± 4 − 1.4 ± 0.4 11 –
CUR-0.01%F127 176 ± 11 − 1.6 ± 0.3 35 –
CUR-0.001%F127 184 ± 30 − 1.3 ± 0.5 10,000 –
CUR-F68 154 ± 20 − 1.4 ± 0.1 150 –
p-THPP-F127 323 ± 8 0.3 ± 0.4 5 –
PS-COOH 210 ± 15 − 50 ± 4 25,000 5,200
a
Mean diameter and ζ-potential were measured via dynamic light scattering and laser Doppler electrophoresis, respectively. Data represent mean ± 
standard error (n ≥ 3).
b
MSDw is calculated from the Stokes-Einstein equation based on average particle diameter and at the time scale of 1s. <MSD>m is the geometric 
ensemble average of MSD at a time scale of 1s.
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